BiotechTube

Ruxolitinib Cream + Vehicle Cream

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NonSegmental Vitiligo

Conditions

NonSegmental Vitiligo

Trial Timeline

Jan 24, 2025 → Mar 13, 2027

NCT ID
NCT06548360

About Ruxolitinib Cream + Vehicle Cream

Ruxolitinib Cream + Vehicle Cream is a phase 3 stage product being developed by Incyte for NonSegmental Vitiligo. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06548360. Target conditions include NonSegmental Vitiligo.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (14)

NCT IDPhaseStatus
NCT06804811Phase 3Recruiting
NCT06959225Phase 3Recruiting
NCT06958211Phase 3Recruiting
NCT06548360Phase 3Recruiting
NCT06238817Phase 3Completed
NCT05764161Phase 3Completed
NCT05755438Phase 3Completed
NCT05635838Phase 2Completed
NCT05593432Phase 2Completed
NCT05593445Phase 2Completed
NCT04896385Phase 2Completed
NCT03745638Phase 3Completed
NCT03745651Phase 3Completed
NCT03099304Phase 2Completed

Competing Products

7 competing products in NonSegmental Vitiligo

See all competitors
ProductCompanyStageHype Score
Ritlecitinib + Ritlecitinib + PlaceboPfizerPhase 3
76
Ritlecitinib + PlaceboPfizerPhase 3
76
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Ruxolitinib CreamIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Povorcitinib + PlaceboIncytePhase 3
74

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74